Key Highlights of the Viral Hepatitis Market 2025-2034: Growth Dynamics, Trends, and Opportunities
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
What is the Predicted CAGR for the Viral Hepatitis Market Over the Forecast Period of 2025 to 2034?
In the past few years, the size of the viral hepatitis market has experienced consistent growth. The market, which is expected to rise from $16.21 billion in 2024 to $16.93 billion in 2025, will have a compound annual growth rate (CAGR) of 4.4%. Factors such as vaccine development, blood screening programs, antiviral drugs, and global health initiatives have played a significant role in the growth witnessed during the historic period.
The market for viral hepatitis is projected to witness consistent expansion in the ensuing years. Its value is anticipated to reach $19.97 billion by 2029, reflecting a compound annual growth rate (CAGR) of 4.2%. The expected growth during the forecast period is primarily due to improved access to treatment, public health regulations, combination therapies, and health equity schemes. Key trends emerging in the forecast timeframe comprise tailored treatment strategies, digital healthcare instruments, AI utilization in disease tracking, and hepatitis C micro-elimination.
How Are the key drivers Contributing to the Expansion of the Viral Hepatitis Market?
The escalating incidence of hepatitis is predicted to drive the expansion of the viral hepatitis market. Hepatitis, an infection of the liver, can be triggered by a variety of infectious viruses and non-infectious substances leading to multiple health concerns. Viruses causing such a condition include Hepatitis A, B, C, D, and E, leading to inflammation and damage to the liver. For example, as per the European Centre for Disease Prevention and Control, a Sweden-based health agency, in April 2024, there were 28,855 recorded instances of hepatitis B virus infection across 30 EU/EEA Member States in 2022. This is a 78% increase from 16,187 cases in 2021. Furthermore, the case count in 2022, totaling 28,420, equates to a crude rate of 8.5 cases per 100,000 people. Hence, the escalating incidence of hepatitis will fuel the growth of the viral hepatitis market. The Viral Hepatitis Market is predicted to grow due to the surge in the amount of research and development activities in this field. The research and development aspect of viral hepatitis covers a wide spectrum of activities such as development of vaccines and antiviral medications, public health interventions, clinical trials, genomic research and epidemiological studies, among others. An uptick in these activities leads to treatment innovations, an increased range for diagnosis and prevention, an enhancement in global health initiatives, and increased competition amongst pharmaceuticals. As evidence, researchers in Melbourne, as per The Peter Doherty Institute for Infection and Immunity in Australia, procured $1.7 million in November 2022 for the forthcoming five years through the mRNA Victoria Activation Program to advance their groundbreaking work in finding a cure for hepatitis B virus infection. Consequently, the surge in the amount of research and development activities fuels the growth of the viral hepatitis market.
Request Your Free Viral Hepatitis Market Report Sample Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=13028&type=smp
Which Companies Are Leading the Charge in Expanding the Viral Hepatitis Market?
Major companies operating in the viral hepatitis market are:
• Pfizer Inc._x000D_
• Johnson & Johnson Co_x000D_
• F Hoffmann-La Roche AG_x000D_
• Merck & Co._x000D_
• AbbVie Inc._x000D_
What Current Trends in the Viral Hepatitis Market Should Industry Players Pay Attention To?
Firms in the viral hepatitis market are making strides in creating new medications and innovations to keep their industry standing. Enhancements in drug development and innovation provide scientific insights by offering a deeper understanding of disease mechanisms, thereby hastening the discovery of new treatments. For example, in November 2022, Gilead Sciences Inc., an American biopharmaceutical firm, reported that the FDA had given approval for the supplemental new drug application (sNDA) for Vemlidy (tenofovir alafenamide) 25 mg tablets. This is to be used as a daily treatment for chronic hepatitis B virus (HBV) infection in children aged 12 years and above who have compensated liver disease. Vemlidy’s approval in pediatric patients was backed by the results of a 24-week Phase 2 clinical trial.
Pre-order Your Report for Quick and Easy Delivery!
https://www.thebusinessresearchcompany.com/report/viral-hepatitis-global-market-report
Which Market Segments Are Driving Strategic Growth and Trends in the Viral Hepatitis Market?
The viral hepatitis market covered in this report is segmented –
1) By Disease Type: Hepatitis A, Hepatitis B, Hepatitis C, Other Disease Types
2) By Diagnosis: Liver Biopsy, Blood Tests, Imaging Tests, Other Diagnosis
3) By Treatment: Antiviral Drugs, Surgery, Vaccine, Immune Modulator Drugs, Other Treatments
4) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration
5) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End-Users
Subsegments:
1) By Hepatitis A: Acute Hepatitis A, Chronic Hepatitis A
2) By Hepatitis B: Acute Hepatitis B, Chronic Hepatitis B, Hepatitis B Carrier
3) By Hepatitis C: Acute Hepatitis C, Chronic Hepatitis C
4) By Other Disease Types: Hepatitis D, Hepatitis E
What Are the Key Regions Powering Growth in the Viral Hepatitis Market?
North America was the largest region in the viral hepatitis market in 2024. The regions covered in viral hepatitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
How Is the Scope and Reach of the Viral Hepatitis Market Defined?
Viral hepatitis refers to a group of infectious diseases caused by different viruses (hepatitis A, B, C, D and E), which primarily affect the liver. The symptoms can vary depending on the specific virus, but common manifestations include fatigue, jaundice, abdominal pain, nausea, vomiting and fever.
Browse Through More Similar Reports By The Business Research Company:
Human Papillomavirus (HPV) Vaccine Global Market Report 2024
Liver Diseases Therapeutics Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/liver-diseases-therapeutics-global-market-report
Fatty Liver Treatment Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/fatty-liver-treatment-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
